Carlos Bonorino Hospital, Av. Caseros 2061 - (1264) Capital Federal, Buenos Aires, Argentina.
Expert Rev Anticancer Ther. 2009 Dec;9(12):1829-47. doi: 10.1586/era.09.143.
Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being the most common site of metastasis. Surgical resection is the only realistic cure for colorectal liver metastases; however only 10-25% of cases are initially resectable. The introduction of combination chemotherapy has improved survival rates by enabling 10-20% cases with previously unresectable hepatic metastases to become amenable to surgery. Recent results with the biologic agent bevacizumab, a chimeric human-mouse monoclonal antibody against VEGF, and cetuximab, a chimeric human-mouse monoclonal antibody against EGF receptor, have shown that they improve clinical surgical outcomes when added to current first-line regimens in patients with metastatic colorectal cancer. Dual biologic therapy in combination with chemotherapy has, however, yielded disappointing results. Identification of biological markers is expected to help determine which patients are most likely to respond to these newer agents and thus improve targeted therapy.
结直肠癌（CRC）常伴有转移性疾病，肝脏是最常见的转移部位。手术切除是结直肠肝转移唯一现实的治愈方法；然而，只有 10-25%的病例最初是可切除的。联合化疗的引入通过使 10-20%以前不可切除的肝转移患者能够接受手术，提高了生存率。最近，生物制剂贝伐单抗（一种针对 VEGF 的嵌合人鼠单克隆抗体）和西妥昔单抗（一种针对 EGF 受体的嵌合人鼠单克隆抗体）的研究结果表明，它们在转移性结直肠癌患者的一线治疗方案中添加后，可改善临床手术结果。然而，双重生物治疗联合化疗的结果令人失望。鉴定生物标志物有望帮助确定哪些患者最有可能对这些新药物产生反应，从而改善靶向治疗。
